Genocea Biosciences, Inc. (NASDAQ:GNCA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Monday, October 16th. The firm presently has a $1.75 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target points to a potential upside of 48.31% from the company’s current price.
According to Zacks, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. “
A number of other brokerages have also recently issued reports on GNCA. Needham & Company LLC upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Monday, July 24th. Cowen and Company restated an “outperform” rating and set a $40.00 target price on shares of Genocea Biosciences in a report on Tuesday, July 25th. ValuEngine cut Genocea Biosciences from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 26th. Piper Jaffray Companies reiterated an “overweight” rating and set a $18.00 price objective (up previously from $17.00) on shares of Genocea Biosciences in a report on Tuesday, July 25th. Finally, Stifel Nicolaus cut Genocea Biosciences from a “buy” rating to a “hold” rating and cut their price objective for the company from $15.00 to $2.50 in a report on Monday, September 25th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. Genocea Biosciences presently has a consensus rating of “Buy” and an average target price of $9.48.
Shares of Genocea Biosciences (NASDAQ:GNCA) traded down 2.07% on Monday, reaching $1.18. 647,178 shares of the company’s stock traded hands. The company has a 50 day moving average of $2.98 and a 200-day moving average of $4.87. Genocea Biosciences has a 52 week low of $1.13 and a 52 week high of $7.29. The stock’s market capitalization is $33.78 million.
Genocea Biosciences (NASDAQ:GNCA) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.08). Equities research analysts forecast that Genocea Biosciences will post ($1.92) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/28/genocea-biosciences-inc-gnca-lifted-to-buy-at-zacks-investment-research.html.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GNCA. Ameriprise Financial Inc. lifted its stake in Genocea Biosciences by 34.1% in the 1st quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 5,068 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in Genocea Biosciences in the 1st quarter valued at approximately $217,000. FMR LLC lifted its stake in Genocea Biosciences by 0.4% in the 1st quarter. FMR LLC now owns 4,274,804 shares of the biotechnology company’s stock valued at $26,033,000 after acquiring an additional 18,574 shares in the last quarter. Geode Capital Management LLC lifted its stake in Genocea Biosciences by 4.7% in the 1st quarter. Geode Capital Management LLC now owns 148,370 shares of the biotechnology company’s stock valued at $903,000 after acquiring an additional 6,708 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. acquired a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $257,000. Hedge funds and other institutional investors own 59.19% of the company’s stock.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.